TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.verified

TCON

Price:

$0.0322

Market Cap:

$109.72K

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I...[Read more]

Industry

Biotechnology

IPO Date

2015-01-30

Stock Exchange

NASDAQ

Ticker

TCON

The ROE as of December 2024 (TTM) for TRACON Pharmaceuticals, Inc. (TCON) is -237.65%

According to TRACON Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -237.65%. This represents a change of 622.57% compared to the average of -32.89% of the last 4 quarters.

TRACON Pharmaceuticals, Inc. (TCON) Historical ROE (quarterly & annually)

How has TCON ROE performed in the past?

The mean historical ROE of TRACON Pharmaceuticals, Inc. over the last ten years is -72.92%. The current -237.65% ROE has changed 225.92% with respect to the historical average. Over the past ten years (40 quarters), TCON's ROE was at its highest in in the September 2022 quarter at 246.41%. The ROE was at its lowest in in the September 2023 quarter at -348.99%.

Quarterly (TTM)
Annual

Average

-72.92%

Median

-87.06%

Minimum

-839.81%

Maximum

443.51%

TRACON Pharmaceuticals, Inc. (TCON) ROE by Quarter and Year

Discovering the peaks and valleys of TRACON Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 415.09%

Maximum Annual ROE = 443.51%

Minimum Annual Increase = -472.34%

Minimum Annual ROE = -839.81%

Quarterly (TTM)
Annual
YearROEChange
2023443.51%8.20%
2022409.90%-267.15%
2021-245.23%254.86%
2020-69.10%-91.77%
2019-839.81%415.09%
2018-163.04%44.98%
2017-112.46%17.99%
2016-95.31%20.96%
2015-78.80%-472.34%
201421.16%-30.42%

TRACON Pharmaceuticals, Inc. (TCON) Average ROE

How has TCON ROE performed in the past?

The current ROE of TRACON Pharmaceuticals, Inc. (TCON) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

202.73%

5-year avg

-60.15%

10-year avg

-72.92%

TRACON Pharmaceuticals, Inc. (TCON) ROE vs. Peers

How is TCON’s ROE compared to its peers?

TRACON Pharmaceuticals, Inc.’s ROE is greater than Rezolute, Inc. (-69.83%), greater than XOMA Corporation (-33.68%), greater than Sio Gene Therapies Inc. (-78.26%), greater than Vincerx Pharma, Inc. (-307.54%), greater than Histogen Inc. (-80.69%), greater than Entera Bio Ltd. (-107.24%), greater than Tempest Therapeutics, Inc. (-187.44%), less than Better Therapeutics, Inc. (129.80%), greater than AN2 Therapeutics, Inc. (-57.63%), greater than Miromatrix Medical Inc. (-70.01%), greater than Inhibikase Therapeutics, Inc. (-350.62%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), less than Candel Therapeutics, Inc. (3.21%), greater than Acurx Pharmaceuticals, Inc. (-67679.28%), greater than Monopar Therapeutics Inc. (-21731.73%), greater than Enochian Biosciences, Inc. (-73.71%), greater than Kronos Bio, Inc. (-64.55%), greater than Cyclerion Therapeutics, Inc. (-55.31%), greater than Larimar Therapeutics, Inc. (-35.87%), less than Addex Therapeutics Ltd (92.06%), greater than Achilles Therapeutics plc (-54.57%),

Build a custom stock screener for TRACON Pharmaceuticals, Inc. (TCON) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TRACON Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

TRACON Pharmaceuticals, Inc. (TCON) and other stocks custom spreadsheet templates

The easiest way to analyze a company like TRACON Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is TRACON Pharmaceuticals, Inc.'s ROE?

How is the ROE calculated for TRACON Pharmaceuticals, Inc. (TCON)?

What is the highest ROE for TRACON Pharmaceuticals, Inc. (TCON)?

What is the 3-year average ROE for TRACON Pharmaceuticals, Inc. (TCON)?

What is the 5-year average ROE for TRACON Pharmaceuticals, Inc. (TCON)?

How does the current ROE for TRACON Pharmaceuticals, Inc. (TCON) compare to its historical average?